Galaxy Balance – Détails, épisodes et analyse

In this debut episode of Galaxy Balance, host Cory Smith sits down with legendary geneticist and futurist George Church for a wide-ranging conversation on the edge of science and imagination. Together they explore the accelerating frontier of AI-driven biology, including protein design, scientific “superintelligence,” and the rise of automated science factories.

George discusses the real state of de-extinction, from woolly mammoths to dire wolves, and the technologies Colossal Biosciences is building to save endangered species. The conversation also dives into the future of human reproduction, IVF breakthroughs, synthetic gametes, and the ethical landscape around editing human embryos.

From mirror-life and biosafety to von Neumann probes, astrobiology, and the search for extraterrestrial life, this episode spans genomics, planetary science, and the future of intelligent civilizations. George also shares thoughts on AI risks, surveillance for biosecurity, his inspiration from science fiction, and what young scientists should focus on now.

A deep, fast-moving, idea-packed episode with one of the most visionary minds in science.

In this episode of Galaxy Balance, Cory Smith sits down with Dr. Case Newsom, an emergency physician and pioneer in psychedelic medicine who helped shape Colorado’s therapeutic psychedelics legislation.

The conversation explores why a single psychedelic experience can lead to lasting change, the neuroscience behind these effects, and the real risks that are often left out of public discussions. Case shares lessons from his work with the Zendo Project, providing peer support at festivals and events, and explains the principle of “sitting, not guiding” to create safe containers for difficult experiences without imposing interpretation.

They dive into the tension between medicalization and legalization, why the FDA rejected MDMA-assisted therapy despite promising data, and how harm, trauma, and abuse can emerge in unregulated spaces. The discussion also examines why bringing psychedelics into regulated, transparent systems may be safer than keeping them underground.

The episode goes further, connecting psychedelics to broader questions about consciousness, community, and the future of intelligence, including a speculative look at what a “psychedelic experience” might mean for artificial general intelligence. Along the way, they discuss emergency medicine, harm reduction, drug policy, and emerging data on psilocybin and longevity.

This conversation is essential listening for clinicians, researchers, policymakers, and anyone curious about consciousness, mental health, and how society navigates powerful transformative technologies.

Aging is often described as damage, wear and tear, or inevitable decline. But what if aging is better understood as a problem of lost biological information?

In this episode of Galaxy Balance, Cory Smith speaks with Chris Bradley, a scientist focused on genome integrity and systems biology, about why maintaining genetic and epigenetic information may be central to extending human healthspan. The conversation explores how cells preserve. or fail to preserve, information over time, why DNA repair and genome stability may be underappreciated levers in aging, and what this framing implies for future interventions.

We discuss how this information-theoretic view of biology reshapes how we think about longevity, why many aging strategies fail to scale, and what it would take to meaningfully slow or reverse age-related decline. Along the way, we examine the limits of current approaches, the tradeoffs between repair and replacement, and how first-principles thinking can clarify which longevity ideas are likely to matter long-term.

This episode is a deep dive into aging as a systems problem, and what it would mean to preserve life’s information rather than simply treat its symptoms.

Topics include:

• Aging as information loss vs. damage accumulation
• Genome integrity and DNA repair
• Epigenetics and biological memory
• Systems biology and scaling longevity interventions
• Constraints on extending human healthspan

How do cells decide what they are, and can we deliberately control that process?

In this episode of Galaxy Balance, Cory Smith is joined by Frank Li, co-founder of Stately Bio, to explore the emerging frontier of cell identity engineering. Frank’s work sits at the intersection of developmental biology, synthetic biology, and therapeutic design, with a focus on understanding, and reprogramming, the molecular rules that govern cell fate.

The conversation dives into how cell identity is established and maintained, why most cell therapies struggle with stability and reproducibility, and how a deeper understanding of developmental programs can enable more precise and durable engineered cell states. They discuss the vision behind Stately Bio, the challenge of translating complex biological control systems into scalable therapeutics, and what it means to move beyond “cell types” toward programmable cellular behaviors.

Zooming out, the episode explores broader questions about control versus emergence in biology, how engineering mindsets are reshaping developmental biology, and what the next decade may bring for regenerative medicine and cell-based therapies.

This is a conversation about building reliable biology, by learning how cells remember who they are.

00:00 - Intro to Galaxy Balance and today's focus on cell engineering & AI innovation
00:36 - Frank Lee's background in computer science and transition into biotech
01:49 - The origins of Stately Bio and its mission to enable non-perturbative cell analysis
02:10 - How machine learning revealed surprising signals in cellular imaging
04:10 - Use cases for live-cell imaging in regenerative medicine and stem cell differentiation
06:00 - The philosophical questions around cell state and biological identity
07:05 - Fighting entropy and examining biological resilience through AI models
08:22 - Integrating AI into manufacturing and regulatory frameworks
09:40 - The future vision: AI empowering biological control and regenerative breakthroughs
11:00 - The role of multi-omics and spatial transcriptomics in cell modeling
12:45 - The expanding frontier of biological design and engineering
14:52 - The societal impact of extending healthspan and aging research
17:05 - Practicing longevity through diet and lifestyle choices
18:55 - How scientific inspiration from science fiction shapes innovation
20:13 - The origin story of Stately Bio's platform technology
22:10 - Moving from fixed protocols to adaptive, AI-driven process control
24:37 - The importance of non-destructive cell analysis for therapy development
27:52 - Commercializing platform technologies while developing therapeutics
31:29 - Regulatory considerations for AI and live-cell analysis in manufacturing
36:51 - How improving cell maturity enhances therapeutic potential
41:27 - Defining cell state through computational modeling and machine learning
45:50 - Integrating multi-omics data with imaging for holistic cell understanding
47:52 - Vision for the company's future and platform expansion
51:59 - The intersection of AI, large language models, and scientific reasoning
55:23 - The inspiring prospects of engineering life and the next technological frontier
57:35 - Frank’s science fiction recommendations and its influence on his mindset
58:42 - Advice for new scientists and engineers entering the field of biology
1:00:29 - Closing remarks and gratitude

Is aging inevitable, or is it an engineering problem waiting to be solved?

In this episode of Galaxy Balance, Cory Smith is joined by Aubrey de Grey, one of the most influential and provocative thinkers in longevity science. Aubrey is best known for reframing aging not as a mysterious, untouchable process, but as the accumulation of specific, repairable forms of biological damage, and for arguing that rejuvenation, not slowing decline, is the most practical path forward.

The conversation explores aging as a systems engineering problem, the concept of longevity escape velocity, and why repairing damage may be fundamentally easier than preventing it. They discuss stem cell replacement, senescent cell clearance, epigenetic programming, DNA damage, cancer as the central bottleneck, and how emerging technologies, including AI, may accelerate progress towards meaningful rejuvenation therapies.

Beyond the science, Aubrey shares his perspective on why society struggles to imagine a positive post-aging future, how dystopian narratives shape public resistance, and why the fight against aging is ultimately a humanitarian mission rather than a personal one.

This episode is a deep dive into the biology, philosophy, and engineering mindset behind one of the most ambitious goals in science: extending healthy human life by repairing the damage of time itself.

https://www.levf.org/

https://www.levf.org/donate

What will it really take for humans to live beyond Earth?

In this episode of Galaxy Balance, Cory Smith sits down with Devon Stork, synthetic biologist and founding member of Pioneer Labs, a nonprofit research institute advancing biotechnology for use in space. Devon’s work focuses on engineering microbes that can survive extreme extraterrestrial environments and transform local resources, like Martian regolith, into usable materials such as soil, building substrates, and biological infrastructure.

The conversation explores why microbes, not humans, are likely to be the first true settlers on Mars; how in-situ resource utilization (ISRU) reshapes the economics and feasibility of space habitation; and why biology’s unique strengths, self-replication, adaptability, and subtle chemistry, make it essential for a multi-planetary future.

We also dive into:

• Designing microbial “chassis” that require minimal infrastructure
• Converting Martian regolith into fertile, perchlorate-free soil
• Open science and rapid communication as a catalyst for frontier research
• The ethics of terraforming and preserving extraterrestrial environments
• How science fiction, evolution, and long-term thinking inform real scientific strategy
• The role of AI and large-scale data in accelerating biological discovery

This episode blends hard science with speculative foresight, offering a grounded look at how life itself may become the foundation for humanity’s expansion beyond Earth.

What if biology could be engineered the way we engineer software?

In this episode of Galaxy Balance, I'm joined by Pranam Chatterjee, Assistant Professor at the University of Pennsylvania and leader of the Programmable Biology Group, working at the intersection of AI, synthetic biology, and next-generation therapeutics.

Pranam's work is shaping a future where generative models can design peptides and biologics from sequence data alone, enabling a new era of programmable medicine.

We explore how Pranam went from studying religion and philosophy to transferring into MIT and building cutting-edge computational tools for biology. We dive into his time in George Church's lab, where early computational strategies helped spark the origins of Gameto, and how that work evolved into today's iPSC-derived ovarian support cell technologies now entering clinical trials.

From there, we go deep into the frontier of AI-driven molecular design:

• Do we actually need protein structure to design effective therapeutics?

• How do we optimize binding, toxicity, permeability, and immunogenicity simultaneously?

• What does "virtual cell" really mean, and why does mapping cell states matter?

• How close are we to "vibe coding biology," where natural language becomes the interface to biological engineering?

We also discuss the future of automation, robotics, and agentic AI in biology, as well as the ethical risks of democratized generative models in biotech.

This conversation is a window into the net phase of human capability: not just ready biology, but designing it.

00:00 - Introduction to AI-driven therapeutic peptide design
01:05 - Background of Pranam Chatterjee's journey from religion to science
02:50 - The evolution of AI models in synthetic biology
05:17 - Key milestones: from modeling to clinical applications like Gameto
08:19 - The founding story of Gameto and major breakthroughs
12:20 - Expanding into disease targeting and regenerative medicine
17:50 - The shift to virtual cell and organism design
22:16 - Tools for peptide design: Peptune and PEPMLM
25:04 - Generative modeling with language models and functional constraints
28:32 - Imagining programmable organisms and mythical creatures
29:41 - Hardware importance and future of vibe-coded biology
31:54 - The role of automation and robotics in biotech labs
33:47 - Mentoring students for the AI-biotech revolution
36:50 - Targeting rare diseases and regulatory considerations
40:34 - Global competition, safety, and ethics in biotech innovation
44:44 - Designing molecules with AI: from complexity to deliverability
45:09 - Data needs: where to find diverse biological datasets
47:49 - The rise of AI agents in scientific research
50:12 - Ethical responsibilities in AI bioengineering
52:38 - Safeguards against harmful biotech applications
55:22 - Thoughts on artificial general intelligence and human purpose
58:40 - How science fiction inspires biotech innovation
1:00:13 - Book recommendations and closing thoughts

In this episode of Galaxy Balance, Cory Smith speaks with Dr. Jonathan Scheiman, co-founder and CEO of FitBiomics, about the science of elite performance, microbiome discovery, and the future of metabolic health.

Jonathan shares his journey from Division I basketball player to biomedicine PhD and postdoctoral researcher in the Church Lab, where unconventional ideas are encouraged and ambitious biology is the norm

His central question was simple but radical: instead of studying disease, what if we studied peak human performance?

That question led to a longitudinal study of Boston Marathon runners, where his team collected microbiome samples before and after intense endurance events. The data revealed a striking pattern. One microorganism, Veillonella, spiked in abundance immediately after the marathon

Further analysis showed that this microbe uniquely metabolizes lactate and converts it into short-chain fatty acids such as propionate

Lactate is often misunderstood as a fatigue molecule. In reality, it is a normal metabolic fuel. When produced in excess during intense exercise, it accumulates in the bloodstream. Scheiman’s work suggests that a portion of circulating lactate is shuttled to the gut, where Veillonella uses it as a carbon source, producing metabolites that may support mitochondrial function, muscle recovery, glucose utilization, and anti-inflammatory pathways

The episode explores:

• How elite athletes may represent a rare biological phenotype comparable in rarity to centenarians
• Why the microbiome can shift rapidly in response to exercise intensity
• The challenges of culturing and scaling strict anaerobic microbes for commercialization
• The regulatory pathway differences between therapeutic microbiome interventions and consumer health products
• How AI and machine learning enabled the discovery of novel microbial signals in complex datasets

The conversation expands into longevity, mitochondrial efficiency, digital health integration, and the idea of FitBiomics as a biological data company rather than simply a probiotic brand

Scheiman also reflects on science fiction, pop culture, and storytelling as forces that shape technological ambition, drawing connections between Marvel, AI, and biotechnology innovation

This episode sits at the intersection of microbiome science, metabolic optimization, artificial intelligence, and the long-term future of human performance.

If the biology of elite athletes can be decoded and translated, the implications extend far beyond sport.

00:00 - Introduction to microbiome insights for human performance
02:20 - Personal journey from sports to biotech innovation
05:28 - How elite athletes inspired microbiome research
09:04 - Approaching human performance limits and societal health impacts
13:48 - Early discoveries: microbiome sampling from Boston Marathon runners
27:19 - The breakthrough finding: Vianella's role in fatigue and endurance
30:19 - Scientific steps to isolate and validate Vianella
33:29 - Regulatory considerations for microbiome supplements versus therapeutics
36:04 - Prevalence of Vianella across different athletes and individuals
40:51 - Microbiome as a dynamic, modifiable biomarker for health and sport
45:37 - Metabolism, mitochondria, and longevity interconnected through microbiome dynamics
49:16 - Influences of science fiction on biotech imagination and vision
57:39 - Future applications: wearables, continuous monitoring, and AI in microbiome health
1:00:46 - Vision for FitBiomics’ role in health innovation and societal impact

Biology is becoming programmable.

In this episode of Galaxy Balance, Cory Smith speaks with Yuanhao Qu, President and Co-Founder of PhyloBio, about the emergence of AI driven biological discovery. Yuanhao represents a new generation of scientists who combine genome engineering with large language models to build systems that can reason about DNA and accelerate research across the life sciences.

The conversation explores Yuanhao’s journey from early cancer research to developing CRISPR-GPT and Biomni, tools designed to help scientists design experiments, analyze data, and navigate the growing complexity of biological research. The discussion then moves to the founding of PhyloBio and the idea of an integrated biology environment where AI agents collaborate with human researchers.

We examine the future of genome engineering, the challenges of delivering gene therapies, and how AI agents may soon assist in designing experiments, generating hypotheses, and exploring massive biological datasets. They also discuss the possibility of automated laboratories, the evolving role of scientists in an AI-augmented research ecosystem, and the ethical boundaries that must guide advances in synthetic biology.

The episode closes with a discussion of science fiction, biosecurity, and the long term vision of AI systems that help humanity understand life at every scale.

If biology becomes a language, the next frontier will belong to those who learn how to speak it.

Phylo is a research lab developing cutting-edge agentic intelligence to accelerate discovery for biomedical scientists. They are building Biomni Lab, an integrated biology environment that leverages the latest AI to transform how biologists work. Explore it at biomni.phylo.bio

Phylo is also actively hiring. Learn more at phylo.bio/careers

Timestamps:

00:00 - Embracing rapid change and AI tools in biology
02:24 - Yuanhao’s background and motivation to cure cancer
04:11 - Analyzing complex diseases with genomics and AI
07:25 - Switching focus to AI-guided discovery and CRISPR engineering
12:13 - Building and deploying CRISPR-GPT to democratize gene editing design
16:23 - How AI enhances the role of scientists rather than replacing them
20:52 - The story behind PhiloBio and its vision to accelerate biotech innovation
24:01 - Developing BioOmni: an AI environment for biological research
28:21 - The future of AI in autonomous labs and the challenge of human-in-the-loop systems
36:33 - Ensuring safety and predicting oncogenic risk in genome engineering
42:49 - Advances needed in delivery mechanisms for gene therapies
45:02 - Insights into human intelligence evolution and AI’s role in discovery
51:04 - The significance of memory, personalization, and continuous learning in AI agents
55:06 - Ethical dilemmas in human germline modification and societal impacts
58:30 - Speculations on life’s prevalence in the universe and the Dark Forest hypothesis
59:46 - Advice for aspiring scientists eager to innovate with AI

In this episode of Galaxy Balance, Cory Smith is joined by Marc Güell, a synthetic biologist working at the frontier of genome engineering, AI-driven biological design, and translational therapeutics.  Marc's work spans programmable genome integration systems, synthetic evolution, and the development of biological tools that extend far beyond what natural evolution has produced.

From his early training in chemistry and engineering to his time in the Church Lab at Harvard and now leading a research group in Barcelona, Marc's career reflects a consistent focus on building new biological technologies. The conversation explores how generative AI is reshaping genome writing, why engineering principles matter in biology, and what it takes to translate deep-tech synthetic biology into real-world applications.

We also discuss the founding of Integra Therapeutics, engineering the skin microbiome as a therapeutic platform, and how imagination influences real life science.

00:00 - How AI enables exploration of unconstrained genotypical spaces in synthetic biology
02:18 - Dr. Guell’s childhood in the Pyrenees fueling his passion for building and discovery
03:14 - From organic chemistry to synthetic genome engineering at Heidelberg and Harvard
05:33 - Recent advances in genome editing: CRISPR, xenotransplantation, and deep tech biotech startups
09:48 - The coming revolution: speaking DNA with AI tools and designing complex genetic circuits
12:30 - Navigating the vast, unconstrained genetic landscape using synthesis-free, AI-guided methods
15:44 - Exploring the complexity of splicing, gene regulation, and the role of AI in modeling biological systems
20:31 - Improving protein design and gene writing with coupled CRISPR and transposases
22:58 - Using AI-generated transposases surpassing natural biodiversity and expanding genotypic networks
27:09 - Strategies for safe, targeted insertions in gene therapy and cell engineering safety sites
30:20 - The mission of Integrate Therapeutics: commercializing AI-driven transposon technologies for cell therapies
34:50 - Challenges facing biotech startups and the need for strategic, cautious growth
39:42 - Engineering skin microbiomes for health and aesthetic applications, from acne to inflammation sensing
44:38 - The incredible potential of microbiome modulation for systemic health and space travel applications
46:46 - Ethical and safety considerations for AI-designed proteins and synthetic biology innovations
49:48 - Cross-cultural perspectives in science: Europe, the US, and China’s unique approaches and collaboration opportunities
51:59 - Automation and AI in experimental biology: new paradigms for high-throughput, in-silico evolution
55:18 - The impact of AI assistants and knowledge agents in accelerating scientific discovery
59:20 - The influence of science fiction: predicting and inspiring future biotechnologies
1:01:23 - Contemplating the nature of life, complexity, and the role of AI in understanding biology’s mysteries
1:04:25 - The power of imagination and science fiction in shaping the next generation of biotech breakthroughs